Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Clin Cancer Res. 2016 Nov 23;23(11):2869–2879. doi: 10.1158/1078-0432.CCR-16-1742

Figure 4.

Figure 4

ROC-325 reduces tumor burden more effectively than HCQ in RCC xenografts. (A) 786-O cells were injected into the flanks of nude mice. Mice were pair-matched and randomized into groups when mean tumor burden reached approximately 100 mm3. Mice were treated with 25, 40, or 50 mg/kg ROC-325 PO and 60 mg/kg HCQ IP QDx5 throughout the course of the study. Tumor volumes were measured twice weekly. Mean ± SEM, n = 5. *Indicates a significant difference in tumor burden compared to vehicle control based on 2-way ANOVA analyses. P < 0.05. (B) ROC-325 is well tolerated in mice. Body weight was determined at the end of the study (Day 46) to quantify drug-induced weight loss. Mean ± SD, n = 5.